Navigation Links
Solos Endoscopy, Inc. Announces Recapitalization Plan for 2011
Date:11/19/2010

BOSTON, Nov. 19, 2010 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce that the Company's management has approved its 2011 recapitalization plan in order to position itself for growth over the next twelve months. The recapitalization plan is designed to increase financial flexibility for Solos and its shareholders.

The recapitalization plan allows Solos greater flexibility to utilize the assets of the Company in the future for corporate purposes; including raising capital, acquisitions or employee compensation, with limited dilution of existing stockholder voting rights.

"We are very pleased that the recapitalization allows us to pursue our existing strategy more aggressively," stated Bob Segersten, President of Solos Endoscopy, Inc.

Throughout the remainder of 2010, the Company will continue its new product development for the MammoView® product line. In addition, Solos plans to achieve market expansion through its efforts to meet the requirements of the ISO 13485 standard and ultimately obtain the CE Mark and the permission to sell medical devices in the European Union and Canada.

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.


'/>"/>
SOURCE Solos Endoscopy, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Solos Endoscopy, Inc. Revenue Grows 34.8% for Third Quarter 2010
2. Solos Endoscopy, Inc. Announces Results of 2010 Annual Shareholder Meeting
3. Solos Endoscopy, Inc. to Hold Annual Shareholder Meeting September 28, 2010
4. Solos Endoscopy, Inc. Develops Relay Lense Adapter System For MammoView® Product Line
5. Solos Endoscopy, Inc. Increases Revenues by 10 Percent for First Quarter 2010 as Compared to First Quarter 2009
6. Solos Endoscopy, Inc. Appoints Experienced CFO To Financial Leadership Amidst Growth
7. Solos Endoscopy, Inc. Granted U.S. Trademark for MammoView(R)
8. Solos Endoscopy, Inc. Set To Develop European Union Conforming CE Mark Technical File
9. Solos Endoscopy, Inc. Set To Develop New Polymer Dilator For MammoView(TM) System
10. Solos Endoscopy, Inc. Retains Expert Resource to Meet Requirements for ISO 13485 Quality Management System Initiative
11. Solos Endoscopy, Inc.s Breast Endoscopy System Featured in February Issue of General Surgery News
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... According to a new market research report "Cartilage Repair/ ... Tissue Scaffolds, Cell-free composites), Application (Hyaline Cartilage, Fibrocartilage), by Region - ... reach USD 779.8 Million by 2021 from USD 414.6 Million in ... of 2016 to 2021. Continue Reading ... ...
(Date:12/5/2016)... PUNE, India , December 5, 2016 According ... by Product Type and by Application - Global Opportunity Analysis and Industry Forecast, ... 2015, and is expected to reach $5,255 million by 2022, growing at a ... in 2015 with more than four-fifths share. Continue ... ...
(Date:12/5/2016)... and PUNE, India , December ... report by Allied Market Research, titled, "Global Cancer Biomarkers Market ... revenue of cancer biomarkers market is projected to reach $15,737 ... CAGR of 13.3% from 2016 to 2022. Omic technologies segment ... 2015 and is expected to maintain its dominance during the ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... ... For many years, Andrew G. Zubinas has accumulated over 130 hardcover ... Lithuanian language and its poetry inspired him in writing “ Forest Lungs ... aspects of a living, breathing forest where nothing ever stays the same. His subjects ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... announced today that nominations will be accepted from December 5, 2016 through ... , Awards include the Information Security Executive® of the Year, which recognizes ...
(Date:12/5/2016)... ... December 05, 2016 , ... Worldwise ... global lifestyle design firm kathy ireland® Worldwide for five additional years, announced by ... into an exclusive licensing agreement three years ago to design and develop the ...
(Date:12/5/2016)... ... December 05, 2016 , ... Progressive ... of L-Citrulline and glutathione to enhance production of nitric oxide (NO). , NitroGenesis ... shown to produce NO twice as effectively and sustains NO blood levels twice ...
(Date:12/5/2016)... ... December 05, 2016 , ... ICA, ... alerting technology to Central Illinois Health Information Exchange (CIHIE) using its Smart ... as the sole sub-recipient participating with the Illinois Health Information Exchange Authority ...
Breaking Medicine News(10 mins):